Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2022-06-23 Karolinska Development AB (publ) Karolinska Development’s portfolio company Promimic presents preclinical results showing decreased bacterial adhesion to implants Pressreleaser Visa Stäng
Pressreleaser | 23 Jun 2022 | Karolinska Development

Karolinska Development’s portfolio company Promimic presents preclinical results showing decreased bacterial adhesion to implants

STOCKHOLM, Sweden, June 23, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Promimic today presented preclinical results tshowing that the company’s HAnano Surface coating technology reduces the risk of adhesion by common pathogenic bacteria by up to 60%.

Promimic develops and markets HAnano Surface, a unique, nanometer-thin surface treatment that aims to improve the anchorage and healing of orthopedic and dental implants into bone tissue. The technology is well established and has so far been applied to over 700,000 implants in clinical use around the world.

The company’s recent in vitro study evaluated the adhesion of three common pathogenic bacterial strains to implants coated with HAnano Surface. The results show that the ability of the bacteria to colonize the implant surface was reduced by 60%, which is of great importance in preventing both infections and implant detachment in patients. The study was conducted with the company’s academic partners at the Instituto de Medicina Molecular in Lisbon, Portugal, and was presented at the European Technology Platform on Nanomedicine (ETPN) conference on June 22.

”Implant-related infections are a major challenge for modern healthcare, resulting in poor fixation, systemic infections and overuse of antibiotics. We are pleased with Promimic’s progress in countering this global challenge,” says Viktor Drvota, CEO of Karolinska Development.

Karolinska Development’s shareholding in Promimic, including indirect ownership by KDev Investments, amounts, after the IPO, to 16.3 percent (1.8 and 14.5 percent, respectively).

For further information, please contact :

Viktor Drvota, CEO, Karolinska Development AB 
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com  

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com

TO THE EDITORS

About Promimic

Promimic is a growth company that manufactures, markets, and sells biomaterials for improved osseointegration (bone healing) to leading companies in the markets for orthopedic and dental implants. The company has its origins in research at Chalmers University of Technology and today has its head office in Mölndal, Sweden, and a sales office in the US. To date, more than 700,000 operations with implants using the Company’s technology have been carried out around the world.

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients’ lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com .

Attachment


2022-06-23 Karolinska Development AB (publ) Karolinska Developments portföljbolag Promimic presenterar prekliniska resultat som visar minskad bakterietillväxt på implantat Pressreleaser Visa Stäng
2022-06-03 Karolinska Development AB (publ) Karolinska Development invests in breakthrough drug project for the treatment of nerve pain Pressreleaser Visa Stäng
2022-06-03 Karolinska Development AB (publ) Karolinska Development investerar i banbrytande läkemedelsprojekt för behandling av nervsmärta Pressreleaser Visa Stäng
2022-05-19 Karolinska Development AB (publ) Karolinska Developments portföljbolag Umecrine Cognition ansöker om start av klinisk fas 2-studie med golexanolon Pressreleaser Visa Stäng
2022-05-19 Karolinska Development AB (publ) Karolinska Development's portfolio company Umecrine Cognition submits a Clinical Trial Application to initiate a phase 2 clinical trial with golexanolone Pressreleaser Visa Stäng
2022-05-17 Karolinska Development AB (publ) Karolinska Developments portföljbolag Aprea Therapeutics förvärvar Atrin Pharmaceuticals Pressreleaser Visa Stäng
2022-05-17 Karolinska Development AB (publ) Karolinska Development’s portfolio company Aprea Therapeutics acquires Atrin Pharmaceuticals Pressreleaser Visa Stäng
2022-05-12 Karolinska Development AB (publ) Karolinska Development’s Annual General Meeting 2022 Pressreleaser Visa Stäng
2022-05-12 Karolinska Development AB (publ) Karolinska Developments årsstämma 2022 Pressreleaser Visa Stäng
2022-05-02 Karolinska Development AB (publ) Karolinska Development’s portfolio company Biosergen prepares Phase 2 study in mucormycosis infected patients Pressreleaser Visa Stäng
2022-05-02 Karolinska Development AB (publ) Karolinska Developments portföljbolag Biosergen förbereder klinisk fas 2-studie med BSG005 mot systemisk svampinfektion Pressreleaser Visa Stäng
2022-04-29 Karolinska Development AB (publ) Karolinska Developments portföljbolag Promimics aktie börjar idag handlas på Nasdaq First North Growth Market Pressreleaser Visa Stäng
2022-04-29 Karolinska Development AB (publ) Karolinska Development’s portfolio company Promimic’s stock starts trading today Pressreleaser Visa Stäng
2022-04-29 Karolinska Development AB (publ) Delårsrapport för januari – mars 2022 Pressreleaser Visa Stäng
2022-04-29 Karolinska Development AB (publ) Interim Report - January-March 2022 Pressreleaser Visa Stäng
2022-04-25 Karolinska Development AB (publ) Karolinska Development’s portfolio company Promimic’s IPO offering fully subscribed Pressreleaser Visa Stäng
2022-04-25 Karolinska Development AB (publ) Karolinska Developments portföljbolag Promimics noteringsemission fulltecknades Pressreleaser Visa Stäng
2022-04-25 Karolinska Development AB (publ) Karolinska Developments portföljbolag OssDsign har rekryterat alla patienter till studien TOP FUSION Pressreleaser Visa Stäng
2022-04-25 Karolinska Development AB (publ) Karolinska Development's portfolio company OssDsign completes patient enrolment to the TOP FUSION study Pressreleaser Visa Stäng
2022-04-12 Karolinska Development AB (publ) Notice of Annual General Meeting in Karolinska Development AB (publ) Pressreleaser Visa Stäng
2022-04-12 Karolinska Development AB (publ) Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma Pressreleaser Visa Stäng
2022-04-04 Karolinska Development AB (publ) Karolinska Development's portfolio company OssDsign enrolls the first patient to the multi-center registry PROPEL Pressreleaser Visa Stäng
2022-04-04 Karolinska Development AB (publ) Karolinska Developments portföljbolag OssDsign inkluderar första patienten till multicenterregistret PROPEL Pressreleaser Visa Stäng
2022-03-25 Karolinska Development AB (publ) Karolinska Developments årsredovisning för 2021 har publicerats Rapporter Visa Stäng
2022-03-25 Karolinska Development AB (publ) Karolinska Development Annual Report 2021 published Rapporter Visa Stäng
2022-03-23 Karolinska Development AB (publ) Karolinska Development's portfolio company OssDsign signs long-term contract with largest hospital network in France Pressreleaser Visa Stäng
2022-03-23 Karolinska Development AB (publ) Karolinska Developments portföljbolag OssDsign tecknar avtal med framstående franskt sjukhusnätverk Pressreleaser Visa Stäng
2022-02-28 Karolinska Development AB (publ) Ändring av antal aktier och röster i Karolinska Development Pressreleaser Visa Stäng
2022-02-28 Karolinska Development AB (publ) Change of number of shares and votes in Karolinska Development Pressreleaser Visa Stäng
2022-02-25 Karolinska Development AB (publ) Bokslutskommuniké för januari – december 2021 Rapporter Visa Stäng
2022-02-25 Karolinska Development AB (publ) Year-end Report - January-December 2021 Rapporter Visa Stäng
2022-02-21 Karolinska Development AB (publ) The rights issue is registered and the trading in Paid Subscription Shares ceases Pressreleaser Visa Stäng
2022-02-21 Karolinska Development AB (publ) Emissionen registrerad och handeln med BTA upphör Pressreleaser Visa Stäng
2022-02-07 Karolinska Development AB (publ) Karolinska Development AB announces definitive outcome in rights issue Pressreleaser Visa Stäng
2022-02-07 Karolinska Development AB (publ) Karolinska Development AB offentliggör slutligt utfall i företrädesemission Pressreleaser Visa Stäng
2022-02-04 Karolinska Development AB (publ) Karolinska Development AB announces preliminary outcome in rights issue Pressreleaser Visa Stäng
2022-02-04 Karolinska Development AB (publ) Karolinska Development AB offentliggör preliminärt utfall i företrädesemission Pressreleaser Visa Stäng
2022-02-03 Karolinska Development AB (publ) Karolinska Developments portföljbolag AnaCardio tar in 33 MSEK för fortsatt klinisk utveckling av sin läkemedelskandidat mot hjärtsvikt Pressreleaser Visa Stäng
2022-02-03 Karolinska Development AB (publ) Karolinska Development's portfolio company AnaCardio raises SEK 33 million to progress clinical development of a novel therapy for heart failure Pressreleaser Visa Stäng
2022-01-26 Karolinska Development AB (publ) Karolinska Development AB (publ): BioStock: Karolinska Development på offensiven med emission Pressreleaser Visa Stäng
2022-01-14 Karolinska Development AB (publ) Karolinska Development AB offentliggör prospekt och ej tidigare offentliggjord finansiell information med anledning av förestående företrädesemission samt bjuder in till investerarpresentationer Pressreleaser Visa Stäng
2022-01-14 Karolinska Development AB (publ) Karolinska Development AB publishes prospectus including previously unpublished financial information due to upcoming rights issue, and invites to investor presentations Pressreleaser Visa Stäng
2022-01-12 Karolinska Development AB (publ) Karolinska Developments extra bolagsstämma 2022 Pressreleaser Visa Stäng
2022-01-12 Karolinska Development AB (publ) Karolinska Development’s Extraordinary General Meeting 2022 Pressreleaser Visa Stäng
2022-01-11 Karolinska Development AB (publ) Karolinska Development's portfolio company Umecrine Cognition presents preclinical data showing that golexanolone reduces neuroinflammation and counteracts motor symptoms Pressreleaser Visa Stäng
2022-01-11 Karolinska Development AB (publ) Karolinska Developments portföljbolag Umecrine Cognition presenterar prekliniska data som visar att golexanolon minskar inflammation i hjärnan och motverkar motoriska symtom Pressreleaser Visa Stäng
2022-01-11 Karolinska Development AB (publ) Karolinska Development's portfolio company Svenska Vaccinfabriken appoints Richard Bethell as new CEO Pressreleaser Visa Stäng
2022-01-11 Karolinska Development AB (publ) Karolinska Developments portföljbolag Svenska Vaccinfabriken utser Richard Bethell till ny vd Pressreleaser Visa Stäng
2021-12-13 Karolinska Development AB (publ) Försäljningen av Karolinska Developments portföljbolag Forendo Pharma till Organon har framgångsrikt slutförts Pressreleaser Visa Stäng
2021-12-13 Karolinska Development AB (publ) Organon’s acquisition of Karolinska Development's portfolio company Forendo Pharma has been successfully completed Pressreleaser Visa Stäng
2021-12-10 Karolinska Development AB (publ) Notice of Extraordinary General Meeting in Karolinska Development AB (publ) Pressreleaser Visa Stäng
2021-12-10 Karolinska Development AB (publ) Aktieägarna i Karolinska Development AB (publ) kallas till extra bolagsstämma Pressreleaser Visa Stäng
2021-12-10 Karolinska Development AB (publ) Karolinska Development AB (publ) föreslår en företrädesemission om cirka 491 MSEK och offentliggör förslag till ny styrelseledamot Pressreleaser Visa Stäng
2021-12-10 Karolinska Development AB (publ) Karolinska Development AB (publ) proposes a rights issue of approximately SEK 491 million, and publishes a proposal for a new Board member Pressreleaser Visa Stäng
2021-12-01 Karolinska Development AB (publ) Karolinska Development’s portfolio company Modus Therapeutics initiates Phase 1b trial of its drug candidate sevuparin Pressreleaser Visa Stäng
2021-12-01 Karolinska Development AB (publ) Karolinska Developments portföljbolag Modus Therapeutics inleder fas 1b-studie av läkemedelskandidaten sevuparin Pressreleaser Visa Stäng
2021-11-22 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Karolinska Development AB Pressreleaser Visa Stäng
2021-11-18 Karolinska Development AB (publ) Interim Report - January-September 2021 Pressreleaser Visa Stäng
2021-11-18 Karolinska Development AB (publ) Delårsrapport för januari – september 2021 Pressreleaser Visa Stäng
2021-11-15 Karolinska Development AB (publ) Karolinska Development AB (publ): BioStock: Organon förvärvar KD-bolaget Forendo Pharma Pressreleaser Visa Stäng
2021-11-11 Karolinska Development AB (publ) Organon förvärvar Karolinska Developments portföljbolag Forendo Pharma till en total köpeskilling om 945 miljoner USD förutsatt att samtliga milstolpar uppnås Pressreleaser Visa Stäng
2021-11-11 Karolinska Development AB (publ) Organon acquires Karolinska Development’s portfolio company Forendo Pharma at a total purchase price of USD 945 million provided fulfilment of all milestones Pressreleaser Visa Stäng
2021-11-10 Karolinska Development AB (publ) Karolinska Development AB (publ): BioStock: Umecrine Cognition visar data inom ny indikation Pressreleaser Visa Stäng
2021-11-09 Karolinska Development AB (publ) Karolinska Development’s portfolio company receives approval to initiate a clinical Phase 1b trial with sevuparin in the Netherlands Pressreleaser Visa Stäng
2021-11-09 Karolinska Development AB (publ) Karolinska Developments portföljbolag Modus Therapeutics erhåller godkännande om start av klinisk fas 1b-studie med sevuparin i Nederländerna Pressreleaser Visa Stäng
2021-11-03 Karolinska Development AB (publ) Karolinska Development’s portfolio company Umecrine Cognition presents new data supporting the development of golexanolone as a treatment of primary biliary cholangitis Pressreleaser Visa Stäng
2021-11-03 Karolinska Development AB (publ) Karolinska Developments portföljbolag Umecrine Cognition presenterar nya forskningsfynd som stöder utvecklingen av golexanolon för behandling av primär biliär kolangit Pressreleaser Visa Stäng
2021-10-27 Karolinska Development AB (publ) Karolinska Development’s portfolio company Dilafor recruits first patient to Phase 2a study of tafoxiparin in women diagnosed with preeclampsia Pressreleaser Visa Stäng
2021-10-27 Karolinska Development AB (publ) Karolinska Developments portföljbolag Dilafor meddelar att första patienten rekryterats till en fas 2a-studie av tafoxiparin i kvinnor med havandeskapsförgiftning Pressreleaser Visa Stäng
2021-10-25 Karolinska Development AB (publ) Karolinska Developments portföljbolag AnaCardio stärker organisationen inför klinisk studie av läkemedelskandidaten AC01 i patienter med hjärtsvikt Pressreleaser Visa Stäng
2021-10-25 Karolinska Development AB (publ) Karolinska Development’s portfolio company AnaCardio strengthens its organization to facilitate clinical trial of the drug candidate AC01 in heart failure Pressreleaser Visa Stäng
2021-10-19 Karolinska Development AB (publ) Karolinska Development's portfolio company Umecrine Cognition to collaborate with University College London to increase insights about golexanolone Pressreleaser Visa Stäng
2021-10-19 Karolinska Development AB (publ) Karolinska Developments portföljbolag Umecrine Cognition ingår samarbete med University College London för att öka kunskapen om golexanolon Pressreleaser Visa Stäng
2021-10-14 Finansinspektionen Finansinspektionen: Korrigering flaggningsmeddelande i Karolinska Development AB Pressreleaser Visa Stäng
2021-10-06 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Karolinska Development AB Pressreleaser Visa Stäng
2021-10-04 Karolinska Development AB (publ) Karolinska Developments portföljbolag OssDsign erhåller utökat marknadsgodkännande av amerikanska läkemedelsverket för OssDsign Cranial PSI Pressreleaser Visa Stäng
2021-10-04 Karolinska Development AB (publ) Karolinska Development's portfolio company OssDsign receives expanded FDA market clearance for OssDsign Cranial PSI Pressreleaser Visa Stäng
2021-09-09 Karolinska Development AB (publ) Karolinska Developments portföljbolag OssDsign inkluderar första patienten i en klinisk studie av det syntetiska bengraftet OssDsign Catalyst Pressreleaser Visa Stäng
2021-09-09 Karolinska Development AB (publ) Karolinska Development's portfolio company OssDsign includes first patient to a clinical trial of the synthetic bone graft OssDsign Catalyst Pressreleaser Visa Stäng
2021-08-24 Karolinska Development AB (publ) Karolinska Development AB (publ): BioStock: KDs halvårsrapport ger en positiv bild Pressreleaser Visa Stäng
2021-08-19 Karolinska Development AB (publ) Interim Report - January-June 2021 Rapporter Visa Stäng
2021-08-19 Karolinska Development AB (publ) Delårsrapport för januari – juni 2021 Rapporter Visa Stäng
2021-08-16 Karolinska Development AB (publ) Karolinska Development's portfolio company OssDsign launches the synthetic bone graft OssDsign Catalyst on the U.S. market Pressreleaser Visa Stäng
2021-08-16 Karolinska Development AB (publ) Karolinska Developments portföljbolag OssDsign lanserar bengraftsubstitutet OssDsign Catalyst i USA Pressreleaser Visa Stäng
2021-08-12 Karolinska Development AB (publ) Karolinska Development's portfolio company Aprea Therapeutics announces that FDA has issued a clinical hold on lymphoid malignancy program Pressreleaser Visa Stäng
2021-08-12 Karolinska Development AB (publ) Karolinska Developments portföljbolag Aprea Therapeutics meddelar att FDA beslutat om uppehåll i bolagets kliniska studieprogram Pressreleaser Visa Stäng
2021-07-22 Karolinska Development AB (publ) Karolinska Developments portföljbolag Aprea Therapeutics rapporterar positiva fas 2-resultat för eprenetapopt Pressreleaser Visa Stäng
2021-07-22 Karolinska Development AB (publ) Karolinska Development’s portfolio company Aprea Therapeutics announces positive Phase 2 results for eprenetapopt Pressreleaser Visa Stäng
2021-07-15 Karolinska Development AB (publ) Karolinska Development’s portfolio company Modus Therapeutics raises SEK 33 million through an oversubscribed issue and now prepares for listing Pressreleaser Visa Stäng
2021-07-15 Karolinska Development AB (publ) Karolinska Developments portföljbolag Modus Therapeutics tillförs SEK 33 miljoner efter en övertecknad emission och förbereder nu inför börsnotering Pressreleaser Visa Stäng
2021-07-14 Karolinska Development AB (publ) Karolinska Development’s portfolio company Umecrine Cognition raises capital through a successful share issue Pressreleaser Visa Stäng
2021-07-14 Karolinska Development AB (publ) Karolinska Developments portföljbolag Umecrine Cognition genomför framgångsrik kapitalanskaffning Pressreleaser Visa Stäng
2021-07-07 Karolinska Development AB (publ) Karolinska Development’s portfolio company Promimic receives market clearance for HAnano Surface in orthopedic oncology in collaboration with Onkos Surgical Pressreleaser Visa Stäng
2021-07-07 Karolinska Development AB (publ) Karolinska Developments portföljbolag Promimic erhåller marknadsgodkännande för HAnano Surface inom onkologisk kirurgi i samarbete med Onkos Surgical Pressreleaser Visa Stäng
2021-07-07 Karolinska Development AB (publ) Karolinska Development sells its holding in Lipidor AB and receives a net of SEK 4 million Pressreleaser Visa Stäng
2021-07-07 Karolinska Development AB (publ) Karolinska Development avyttrar innehav i portföljbolaget Lipidor AB och erhåller netto 4 miljoner SEK Pressreleaser Visa Stäng
2021-06-24 Karolinska Development AB (publ) Karolinska Development AB (publ): BioStock: Karolinska Developments vd kommenterar senaste tidens nyhetsflöde Pressreleaser Visa Stäng
2021-06-17 Karolinska Development AB (publ) Karolinska Development expands its portfolio through new investment in AnaCardio Pressreleaser Visa Stäng
2021-06-17 Karolinska Development AB (publ) Karolinska Development expanderar sin portfölj genom nyinvestering i AnaCardio Pressreleaser Visa Stäng
2021-06-17 Karolinska Development AB (publ) Karolinska Development increases book value of Dilafor that is indirectly owned via KDev Investments AB by SEK 450 million Pressreleaser Visa Stäng
2021-06-17 Karolinska Development AB (publ) Karolinska Development ökar det bokförda värdet av innehavet i portföljbolaget Dilafor som ägs indirekt via KDev Investments AB med SEK 450 miljoner Pressreleaser Visa Stäng
2021-06-17 Karolinska Development AB (publ) Karolinska Developments portföljbolag Aprea Therapeutics uppnår primärt utfallsmått i kombinationsterapi av AML med eprenetapopt Pressreleaser Visa Stäng
2021-06-17 Karolinska Development AB (publ) Karolinska Development’s portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary efficacy endpoint in combination therapy of acute myeloid leukemia Pressreleaser Visa Stäng
2021-06-15 Karolinska Development AB (publ) Karolinska Developments portföljbolag Modus Therapeutics och Imperial College London planerar klinisk studie av sevuparin mot svår malaria Pressreleaser Visa Stäng
2021-06-15 Karolinska Development AB (publ) Karolinska Development’s portfolio company Modus Therapeutics and Imperial College London to conduct clinical study of sevuparin in severe malaria Pressreleaser Visa Stäng
2021-06-11 Karolinska Development AB (publ) Karolinska Developments portföljbolag Promimic undersöker förutsättningarna för en listning på Nasdaq First North Growth Market Pressreleaser Visa Stäng
2021-06-11 Karolinska Development AB (publ) Karolinska Development’s portfolio company Promimic evaluates the possibility of a listing on Nasdaq First North Growth Market Pressreleaser Visa Stäng
2021-06-10 Karolinska Development AB (publ) Karolinska Development’s portfolio company Biosergen raises SEK 50 million through a successful unit offering and prepares for IPO Pressreleaser Visa Stäng
2021-06-10 Karolinska Development AB (publ) Karolinska Developments portföljbolag Biosergen tillförs SEK 50 miljoner genom en fulltecknad företrädesemission och förbereder notering Pressreleaser Visa Stäng
2021-06-01 Karolinska Development AB (publ) Karolinska Developments portföljbolag Dilafor presenterar positiva resultat från fas 2b-studie av tafoxiparin Pressreleaser Visa Stäng
2021-06-01 Karolinska Development AB (publ) Karolinska Development’s portfolio company Dilafor presents positive results from a phase 2b study of tafoxiparin Pressreleaser Visa Stäng
2021-05-21 Karolinska Development AB (publ) Karolinska Developments portföljbolag Umecrine Cognition förbereder notering på Nasdaq First North Growth Market Pressreleaser Visa Stäng
2021-05-21 Karolinska Development AB (publ) Karolinska Development's portfolio company Umecrine Cognition initiates preparations for listing on Nasdaq First North Growth Market Pressreleaser Visa Stäng
2021-05-12 Karolinska Development AB (publ) Karolinska Development’s portfolio company OssDsign raises SEK 270 million through an oversubscribed rights issue Pressreleaser Visa Stäng
2021-05-12 Karolinska Development AB (publ) Karolinska Developments portföljbolag OssDsign tillförs SEK 270 miljoner genom en övertecknad företrädesemission med utnyttjat övertilldelningsoptionsprogram Pressreleaser Visa Stäng
2021-05-05 Karolinska Development AB (publ) Karolinska Development’s Annual General Meeting 2021 Pressreleaser Visa Stäng
2021-05-05 Karolinska Development AB (publ) Karolinska Developments årsstämma 2021 Pressreleaser Visa Stäng
2021-05-04 Karolinska Development AB (publ) Karolinska Development AB (publ): BioStock: Karolinska Development mot nya milstolpar med förnyat team Pressreleaser Visa Stäng
2021-04-29 Karolinska Development AB (publ) Interim Report - January-March 2021 Pressreleaser Visa Stäng
2021-04-29 Karolinska Development AB (publ) Delårsrapport för januari – Mars 2021 Pressreleaser Visa Stäng
2021-04-26 Karolinska Development AB (publ) Karolinska Development AB (publ): BioStock: KD-bolaget Umecrine publicerar resultat i ansedd tidskrift Pressreleaser Visa Stäng
2021-04-22 Karolinska Development AB (publ) Karolinska Developments portföljbolag Umecrine Cognition publicerar kliniska forskningsresultat i högt ansedd tidskrift Pressreleaser Visa Stäng
2021-04-22 Karolinska Development AB (publ) Karolinska Development's portfolio company Umecrine Cognition publishes clinical research results in a highly regarded journal Pressreleaser Visa Stäng
2021-04-09 Karolinska Development AB (publ) Karolinska Developments portföljbolag Aprea Therapeutics erhåller särläkemedelsstatus i USA för eprenetapopt vid behandling av AML Pressreleaser Visa Stäng
2021-04-09 Karolinska Development AB (publ) Karolinska Development’s portfolio company Aprea Therapeutics receives orphan drug designation for eprenetapopt in AML Pressreleaser Visa Stäng
2021-04-06 Karolinska Development AB (publ) Karolinska Developments portföljbolag Dilafor har slutfört inklusionen till fas 2b-studie av läkemedelskandidaten tafoxiparin Pressreleaser Visa Stäng
2021-04-06 Karolinska Development AB (publ) Karolinska Development’s portfolio company Dilafor completes patient inclusion to Phase 2b trial of its drug candidate tafoxiparin Pressreleaser Visa Stäng
2021-03-30 Karolinska Development AB (publ) Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma Pressreleaser Visa Stäng
2021-03-30 Karolinska Development AB (publ) Notice of Annual General Meeting in Karolinska Development AB (publ) Pressreleaser Visa Stäng
2021-03-25 Karolinska Development AB (publ) Karolinska Developments årsredovisning för 2020 har publicerats Rapporter Visa Stäng
2021-03-25 Karolinska Development AB (publ) Karolinska Development Annual Report 2020 published Rapporter Visa Stäng
2021-03-15 Karolinska Development AB (publ) Karolinska Development's portfolio company Modus Therapeutics initiates preparations for listing on Nasdaq First North Growth Market Pressreleaser Visa Stäng
2021-03-15 Karolinska Development AB (publ) Karolinska Developments portföljbolag Modus Therapeutics förbereder notering på Nasdaq First North Growth Market Pressreleaser Visa Stäng
2021-03-11 Karolinska Development AB (publ) Karolinska Development AB (publ): BioStock: Karolinska Developments Modus Therapeutics utvecklar sevuparin mot sepsis Pressreleaser Visa Stäng
2021-03-10 Karolinska Development AB (publ) Karolinska Developments portföljbolag Modus Therapeutics förbereder kliniskt utvecklingsprogram för sevuparin vid sepsis / septisk chock Pressreleaser Visa Stäng
2021-03-10 Karolinska Development AB (publ) Karolinska Development's portfolio company Modus Therapeutics prepares clinical development program of sevuparin in sepsis/septic shock Pressreleaser Visa Stäng
2021-03-05 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Karolinska Development AB Pressreleaser Visa Stäng
2021-03-05 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Karolinska Development AB Pressreleaser Visa Stäng
2021-03-04 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Karolinska Development AB Pressreleaser Visa Stäng
2021-03-04 Karolinska Development AB (publ) Karolinska Development AB (publ): BioStock: Karolinska Developments Forendo Pharma går vidare till fas II Pressreleaser Visa Stäng
2021-03-03 Karolinska Development AB (publ) Karolinska Development AB (publ): BioStock: KD-bolaget OssDsign satsar med ny strategi och emission Pressreleaser Visa Stäng
2021-03-03 Karolinska Development AB (publ) Karolinska Developments portföljbolag Forendo Pharma tar FOR-6219 vidare till fas 2-studie baserat på positiva fas 1-resultat Pressreleaser Visa Stäng
2021-03-03 Karolinska Development AB (publ) Karolinska Development’s portfolio company Forendo Pharma advances FOR-6219 to Phase 2 based on positive Phase 1 data Pressreleaser Visa Stäng
2021-03-02 Karolinska Development AB (publ) Karolinska Development’s portfolio company OssDsign announces a fully guaranteed rights issue and launches new corporate strategy Pressreleaser Visa Stäng
2021-03-02 Karolinska Development AB (publ) Karolinska Developments portföljbolag OssDsign genomför en fullt garanterad företrädesemission och lanserar ny bolagsstrategi Pressreleaser Visa Stäng
2021-03-01 Karolinska Development AB (publ) Karolinska Development appoints Per Aniansson as CFO and Investment Director Pressreleaser Visa Stäng
2021-03-01 Karolinska Development AB (publ) Karolinska Development utser Per Aniansson till ny finansdirektör och Investment Director Pressreleaser Visa Stäng
2021-02-26 Karolinska Development AB (publ) Karolinska Development appoints Johan Dighed as Deputy CEO Pressreleaser Visa Stäng
2021-02-26 Karolinska Development AB (publ) Karolinska Development utser Johan Dighed till vice vd Pressreleaser Visa Stäng
2021-02-19 Karolinska Development AB (publ) Karolinska Development’s Extraordinary General Meeting 2021 Pressreleaser Visa Stäng
2021-02-19 Karolinska Development AB (publ) Karolinska Developments extra bolagsstämma 2021 Pressreleaser Visa Stäng
2021-02-16 Karolinska Development AB (publ) Karolinska Development AB (publ): BioStock: Milstolpar i sikte för Karolinska Development Pressreleaser Visa Stäng
2021-02-11 Karolinska Development AB (publ) Bokslutskommuniké för januari – December 2020 Rapporter Visa Stäng
2021-02-11 Karolinska Development AB (publ) Year-end Report - January-December 2020 Rapporter Visa Stäng
2021-01-26 Karolinska Development AB (publ) Notice of Extraordinary General Meeting in Karolinska Development AB (publ) Pressreleaser Visa Stäng
2021-01-26 Karolinska Development AB (publ) Aktieägarna i Karolinska Development AB (publ) kallas till extra bolagsstämma Pressreleaser Visa Stäng

Kommande händelser

19 Aug 2022 | Kvartalsrapport 2022-Q2
18 Nov 2022 | Kvartalsrapport 2022-Q3